Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The multicenter real-world report of the efficacies of 14-day esomeprazole-based and rabeprazole-based high-dose dual therapy in first-line Helicobacter pylori eradication in Taiwan.
Tai WC, Wu IT, Wang HM, Huang PY, Yao CC, Wu CK, Yang SC, Liang CM, Hsu PI, Chuah SK. Tai WC, et al. Among authors: yao cc. J Microbiol Immunol Infect. 2024 Mar 4:S1684-1182(24)00046-X. doi: 10.1016/j.jmii.2024.02.009. Online ahead of print. J Microbiol Immunol Infect. 2024. PMID: 38461114 Free article.
Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice.
Hung KT, Yang SC, Wu CK, Wang HM, Yao CC, Liang CM, Tai WC, Wu KL, Kuo YH, Lee CH, Chuah SK. Hung KT, et al. Among authors: yao cc. Infect Drug Resist. 2021 Mar 25;14:1239-1246. doi: 10.2147/IDR.S304711. eCollection 2021. Infect Drug Resist. 2021. PMID: 33790594 Free PMC article.
The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance.
Huang TH, Yang SC, Tai WC, Liang CM, Kuo CM, Yao CC, Wu CK, Kuo YH, Chou YP, Lee CH, Wu KL, Chuah SK. Huang TH, et al. Among authors: yao cc. Biomed J. 2021 Dec;44(6 Suppl 2):S275-S281. doi: 10.1016/j.bj.2020.11.012. Epub 2020 Nov 24. Biomed J. 2021. PMID: 35292265 Free PMC article.
The Efficacy and Safety of 14-day Rabeprazole Plus Amoxicillin High Dose Dual Therapy by Comparing to 14-day Rabeprazole-Containing Hybrid Therapy for the Naïve Helicobacter pylori Infection in Taiwan: A Randomized Controlled Trial.
Tai WC, Yang SC, Yao CC, Wu CK, Liu AC, Lee CH, Kuo YH, Chuah SK, Liang CM. Tai WC, et al. Among authors: yao cc. Infect Dis Ther. 2023 May;12(5):1415-1427. doi: 10.1007/s40121-023-00811-3. Epub 2023 May 3. Infect Dis Ther. 2023. PMID: 37133673 Free PMC article.
First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.
Liang CM, Kuo MT, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Wang HM, Yao CC, Tsai CE, Wang YK, Wang JW, Huang CF, Wu DC, Chuah SK; Taiwan Acid-Related Disease Study Group. Liang CM, et al. Among authors: yao cc. World J Gastroenterol. 2017 Dec 21;23(47):8395-8404. doi: 10.3748/wjg.v23.i47.8395. World J Gastroenterol. 2017. PMID: 29307999 Free PMC article. Clinical Trial.
Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
Chiang HH, Wu DC, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Yao CC, Tsai CE, Liang CM, Wang YK, Wang JW, Huang CF, Chuah SK; Taiwan Acid-Related Disease Study Group. Chiang HH, et al. Among authors: yao cc. Drug Des Devel Ther. 2019 Apr 26;13:1347-1356. doi: 10.2147/DDDT.S193559. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31118571 Free PMC article. Clinical Trial.
176 results